🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Luye Pharma Group clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Luye Pharma Group as lead sponsor. Synced 26 Sep 2026
13Current trials
5Recruiting now
8Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Luye Pharma Group is the lead sponsor of 13 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are LPM6690176, LY03017 and LY03020. The most-studied condition is Schizophrenia.

ClinicalTrials.gov trials by status

  • Recruiting538%
  • Not yet open538%
  • Active, closed215%
  • By invitation18%

Trials by phase

  • Phase 1754%
  • Phase 1/2215%
  • Phase 2215%
  • Phase 3215%
01

Clinical trials sponsored by Luye Pharma Group

13 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
NCT06731868 · ClinicalTrials.gov ↗ · Tardive Dyskinesia (TD)
Phase 1/2 Recruiting 2025-01 China
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
NCT06128837 · ClinicalTrials.gov ↗ · Relapsed Small Cell Lung Cancer
Phase 3 Recruiting 2024-03 China
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
NCT06240546 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2024-03 China
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
NCT07230652 · ClinicalTrials.gov ↗ · Schizophrenia, Alzheimer's Disease Psychosis
Phase 1 Recruiting 2025-08 China
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
NCT06496048 · ClinicalTrials.gov ↗ · Relapsed Small Cell Lung Cancer
Phase 3 Recruiting 2024-09 China
Mass Balance Study of [14C] LPM3770164 in Healthy Participants
NCT07516899 · ClinicalTrials.gov ↗ · Huntington Disease
Phase 1 Not yet open 2026-04 China
A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia
NCT07396870 · ClinicalTrials.gov ↗ · Schizophrenia
Drug: LY03020
Phase 2 Not yet open 2026-03 China
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
NCT07391566 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (mCRC)
Phase 1/2 Not yet open 2026-03 China
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
NCT06980207 · ClinicalTrials.gov ↗ · Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
Drug: LY03017
Phase 1 Not yet open 2025-05 China
Effect of Food and Age on the Pharmacokinetics of LY03017
NCT06793995 · ClinicalTrials.gov ↗ · Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
Drug: LY03017
Phase 1 Not yet open 2025-02 China
To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects
NCT07371065 · ClinicalTrials.gov ↗ · Major Depressive Disorder
Phase 1 By invitation 2025-10 China
A Food Effect Study of LY03020 in Healthy Subjects
NCT07292233 · ClinicalTrials.gov ↗ · Schizophrenia, Alzheimer's Disease Psychosis
Drug: LY03020
Phase 1 Active, closed 2025-07 China
Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)
NCT07236476 · ClinicalTrials.gov ↗ · Assisted Reproduction
Phase 2 Active, closed 2024-10 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Luye Pharma Group trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Luye Pharma Group trials

13 conditions
Schizophrenia3Alzheimer's Disease Psychosis3Relapsed Small Cell Lung Cancer2Negative Symptoms of Schizophrenia2Tardive Dyskinesia (TD)1Huntington Disease1Assisted Reproduction1Metastatic Colorectal Cancer (mCRC)1Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis1Hallucinations and Delusions Associated With Parkinson Disease Psychosis1Advanced Solid Tumor1Parkinson Disease Psychosis1Major Depressive Disorder1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China135

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Schizophrenia

SponsorTrials
Shanghai Mental Health Center8
Bristol-Myers Squibb7
China Medical University Hospital7
Central South University7
Neurocrine Biosciences6
University of Pittsburgh3
Vigonvita Life Sciences3
Tianjin Anding Hospital3
Vanda Pharmaceuticals2
Karuna Therapeutics, Inc., a Bristol Myers Squibb company2

Sponsors with the most current trials registered for this condition.

06

Questions about Luye Pharma Group trials

How many clinical trials does Luye Pharma Group sponsor?

Luye Pharma Group is the lead sponsor of 13 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Luye Pharma Group trials recruiting?

Yes. 5 of its 13 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Luye Pharma Group testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are LPM6690176 (2), LY03017 (2), LY03020 (2), Bevacizumab (1) and Folfiri (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.